Abstract
This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 55-62 |
| Number of pages | 8 |
| Journal | Journal of neuro-oncology |
| Volume | 37 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 25 1998 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Neurology
- Clinical Neurology
- Cancer Research
Cite this
}
A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392). / Hellman, Richard; Neuberg, Donna S.; Wagner, Henry; Grunnet, Margaret; Robins, H. Ian; Karp, Daniel; Flynn, Patrick; Adams, George.
In: Journal of neuro-oncology, Vol. 37, No. 1, 25.02.1998, p. 55-62.Research output: Contribution to journal › Article
TY - JOUR
T1 - A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)
AU - Hellman, Richard
AU - Neuberg, Donna S.
AU - Wagner, Henry
AU - Grunnet, Margaret
AU - Robins, H. Ian
AU - Karp, Daniel
AU - Flynn, Patrick
AU - Adams, George
PY - 1998/2/25
Y1 - 1998/2/25
N2 - This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.
AB - This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.
UR - http://www.scopus.com/inward/record.url?scp=0031882420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031882420&partnerID=8YFLogxK
U2 - 10.1023/A:1005867520788
DO - 10.1023/A:1005867520788
M3 - Article
C2 - 9525838
AN - SCOPUS:0031882420
VL - 37
SP - 55
EP - 62
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 1
ER -